Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population

NCT07388056 | Completed DMC FDA Drug

• 1 other identifier: MTU-EC-IM-1-301/65
• Study Type: observational
• Target: 169
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is: • Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.

Conditions

Cancer-associated Thrombosis

Outcome Measures

Primary Outcomes (1)

• Recurrent thrombosis

  cumulative incidence of recurrent thrombosis

  After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.

Secondary Outcomes (2)

• Anticoagulant related bleeding

  After completing 6-month of treatment to the time that anticoagulant stop or bleeding occurred through study completion, at the end of December 2025.

• Overall survival

  The time from VTE diagnosis to last follow up or die through study completion, at the end of December 2025.

Study Arms (2)

Therapeutic dose anticoagulant group

including patients with the standard therapeutic dose-administered after the initial six-month treatment period.

Drug: Anticoagulant

Prophylactic dose anticoagulant group

including patients with the doses lower than therapeutic dose-administered at any point after the initial six-month treatment period.

Drug: Anticoagulant

Interventions

Anticoagulant DRUG

warfarin at therapeutic level (INR 2-3), Low molecular weight heparin (LMWH) DOAC

Prophylactic dose anticoagulant group; Therapeutic dose anticoagulant group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients treated at Thammasat University Hospital or Panyananthaphikkhu Chonprathan Medical Center.

You may not qualify if:

• Adult patients aged ≥18 years
• Histopathologically confirmed cancer
• Radiologically confirmed diagnosis of cancer-associated thrombosis (CAT)

Sponsors & Collaborators

• Thammasat University: lead

MeSH Terms

Interventions

Anticoagulants

Intervention Hierarchy (Ancestors)

Hematologic Agents; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Hematology, Internal medicine, Faculty of medicine

Study Record Dates

• First Submitted: January 21, 2026
• First Posted: February 4, 2026
• Study Start: January 1, 2012
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: February 4, 2026

Record last verified: 2026-01